一次抗体と二次抗体-抗-エピトープタグ、免疫測定、Cas 9 » Primary Antibodies » Immune Checkpoint Antibodies » Anti-Obinutuzumab Antibody (16B7), mAb, Mouse
Anti-Obinutuzumab Antibody (16B7), MAb, Mouse

Standard curve of Obinutuzumab Sandwich ELISA. The Obinutuzumab Sandwich ELISA assay is developed by using Anti-Obinutuzumab Antibody (18H8), mAb, Mouse (GenScript, A01945-40) and Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) as capture and detection antibody, respectively.
In this ELISA assay, Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) was labeled with Biotin. GenScript can provide customized conjugation service for this product per customer's request. The sensitivity of detecting Obinutuzumab is about 30 pg/ml.

Anti-Obinutuzumab Antibody (16B7), MAb, Mouse

Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) binds with Obinutuzumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
Coating antigen: Obinutuzumab, 1 µg/ml.
Anti-Obinutuzumab antibody (GenScript, A01946-40) dilution start from 1,000 ng/ml.
EC50= 8.148 ng/ml.

Anti-Obinutuzumab Antibody (16B7), mAb, Mouse

The product is specific for Obinutuzumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01945-40, Anti-Obinutuzumab Antibody (18H8), mAb, Mouse.
A01946
¥25,548.00

Ask us a question
Overview
Specificity The product is specific for Obinutuzumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01945-40, Anti-Obinutuzumab Antibody (18H8), mAb, Mouse.
Host Species Mouse
Immunogen Obinutuzumab
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-1 µg/ml

Properties
Form Lyophilized
Storage Buffer lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Purification Protein A affinity column
Isotype Mouse IgG2a,κ
Clonality Monoclonal
Clone ID 16B7
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples
  • Anti-Obinutuzumab Antibody (16B7), MAb, Mouse
    • Anti-Obinutuzumab Antibody (16B7), MAb, Mouse

    Standard curve of Obinutuzumab Sandwich ELISA. The Obinutuzumab Sandwich ELISA assay is developed by using Anti-Obinutuzumab Antibody (18H8), mAb, Mouse (GenScript, A01945-40) and Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) as capture and detection antibody, respectively.
    In this ELISA assay, Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) was labeled with Biotin. GenScript can provide customized conjugation service for this product per customer's request. The sensitivity of detecting Obinutuzumab is about 30 pg/ml.

  • Anti-Obinutuzumab Antibody (16B7), MAb, Mouse
    • Anti-Obinutuzumab Antibody (16B7), MAb, Mouse

    Anti-Obinutuzumab Antibody (16B7), mAb, Mouse (GenScript, A01946-40) binds with Obinutuzumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
    Coating antigen: Obinutuzumab, 1 µg/ml.
    Anti-Obinutuzumab antibody (GenScript, A01946-40) dilution start from 1,000 ng/ml.
    EC50= 8.148 ng/ml.


Background
Target Background Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Synonyms Mouse monoclonal to Gazyva

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.